InfuSystem (INFU) Q1 2026: Wound Care Revenue Jumps 112% as Compression Partnerships Accelerate Segment Mix Shift
InfuSystem’s Q1 marked a strategic inflection, as wound care revenue more than doubled and new compression device partnerships began to reshape the business mix. Despite a headline revenue decline tied to a major contract reset, margin expansion and operational leverage offset top-line softness, with management signaling a path to higher-return growth and improved cost discipline as new systems come online. Investors should watch for ERP-driven productivity gains and the continued transformation of the patient services segment as key drivers for the coming quarters.
Summary
- Wound Care Inflection: Compression device partnerships are rapidly scaling segment contribution.
- ERP Integration: New system centralizes workflows, setting stage for margin and productivity upside.
- Business Mix Shift: Patient services growth offsets device revenue reset, underpinning margin resilience.
Business Overview
InfuSystem is a healthcare services provider specializing in infusion therapy, device rental, and biomedical services for oncology, wound care, and pain management. The business operates two main segments: Patient Services, which generates revenue from providing medical devices and support directly to patients and clinics, and Device Solutions, focused on equipment rental, sales, and servicing for healthcare providers. Revenue is balanced between recurring service contracts and transactional device sales, with recent strategic emphasis on expanding higher-margin, less capital-intensive patient care offerings.
Performance Analysis
Q1 2026 results reflected a deliberate transition in InfuSystem’s revenue composition. Headline revenue fell 3% year-over-year, primarily due to the restructuring of a major GE Healthcare contract within Device Solutions. Adjusting for this, pro forma revenue grew modestly, highlighting underlying momentum in core patient services lines. The patient services segment grew 6.4%, driven by increased oncology treatment volumes and a standout 112% surge in wound care revenue, as new compression device partnerships unlocked faster growth. Oncology, the largest subsegment, posted steady but slower growth, while pain management remained stable with new customer additions but no immediate lift from reimbursement changes.
Despite lower total revenue, gross profit rose 3% and gross margin expanded 320 basis points to just over 58%, reflecting a higher mix of patient services and improved cost controls. Device Solutions saw revenue decline but achieved a 7% gross margin increase within field services, as smaller, higher-margin projects partially replaced lost GE volume. SG&A fell 2.2% year-over-year, aided by lower one-time costs and disciplined expense management, though offset by ongoing investments in IT systems and wage inflation. Adjusted EBITDA margin held above 18%, with ERP project costs peaking but expected to taper in coming quarters.
- Segment Mix Shift: Patient services now comprise a larger share of gross profit, driving margin expansion as wound care outpaces legacy device sales.
- Compression Device Ramp: New partnerships in wound care are accelerating revenue and improving working capital efficiency due to less capital-intensive growth.
- ERP Investment: System integration is expected to unlock further productivity and cost optimization, with benefits projected to materialize in 2027.
Cash flow from operations dipped due to working capital build, but capital expenditures fell as the business leaned into less asset-heavy revenue streams. Liquidity remains robust, with net leverage at just 0.56x and $57 million in available liquidity, supporting continued investment and share repurchases.
Executive Commentary
"After putting this application in place and retiring several legacy systems, much of our data is now integrated, workflows are connected, and the many processes supporting our various business lines run through a common platform, not multiple disparate systems. While we continue to make final adjustments, resolve open items on the punch list, and get over the learning curve, we are starting to focus on capturing the benefits that we anticipate will start to pay back our investments."
Carrie Lachance, President and Chief Executive Officer
"Despite the decrease in net revenue, gross profit for the first quarter of 2026 was $19.7 million, representing an increase of $515,000 or 3% over the prior year first quarter. The gross margin percentage at just over 58% increased by 3.2% from the prior year amount."
Barry, Chief Financial Officer
Strategic Positioning
1. Wound Care and Compression Devices Drive Growth
Wound care now represents 6% of revenue and is on track for double-digit share as new partnerships in compression devices (PCDs, pneumatic compression devices) deliver rapid volume gains. The Lymphedema Patient Treatment Act and reliable partner paperwork have resolved prior billing hurdles, positioning InfuSystem to capitalize on reimbursement tailwinds and market expansion.
2. Patient Services Margin Expansion
Patient services gross margin increased to 64.8% as higher sales and lower device disposal costs improved profitability. The shift toward recurring, higher-margin patient care revenue is intentionally reducing capital intensity and stabilizing cash flow, a key lever in the company’s long-term value creation strategy.
3. ERP Rollout and Operational Leverage
The new ERP (Enterprise Resource Planning) system consolidates data and workflows across business lines, enabling better cost analysis, pricing decisions, and device utilization. While short-term costs are elevated, management expects productivity gains and cost savings to begin accruing in 2027, with system enhancements prioritized for rapid payback.
4. Device Solutions Reset and Service Mix
Device Solutions revenue declined due to the GE contract reset and a prior-year rental buyout, but the business is now focused on smaller, higher-margin service projects. This trade-off reduced headline revenue but improved overall gross margin and earnings quality.
5. Capital Allocation Discipline
With capital expenditures falling and share repurchases ongoing, InfuSystem is signaling confidence in its liquidity and the sustainability of its strategy. The company’s low leverage and fixed-rate debt structure provide flexibility to support growth initiatives or weather volatility.
Key Considerations
This quarter’s results underscore a business model transition, with InfuSystem leaning into patient-centric growth and technology-enabled efficiency while navigating legacy contract resets and cost inflation.
Key Considerations:
- Wound Care Momentum: Compression device growth is critical for hitting the upper end of revenue guidance and sustaining margin gains.
- ERP Productivity Payback: The timeline for cost savings and operational improvements will be a key watchpoint through 2027.
- Device Solutions Revenue Reset: Successful replacement of lost GE contract revenue with higher-margin service work will determine the segment’s long-term role.
- Oncology Platform Migration: The planned move to the Apollo-based RCM (Revenue Cycle Management) platform remains on track for late 2026, with potential to further streamline billing and collections.
Risks
Execution on ERP integration poses short-term disruption risk, with any billing or operational hiccups potentially impacting cash flow and customer satisfaction. Compression device growth is reliant on strong partner execution and stable reimbursement, and any policy or paperwork setbacks could slow momentum. Device Solutions faces continued headwinds from legacy contract roll-offs, requiring successful pivot to new service models. Wage and healthcare cost inflation remain persistent pressures on margin structure.
Forward Outlook
For Q2 2026, InfuSystem expects:
- Stable adjusted EBITDA margins in the low to mid 20% range, inclusive of ERP costs
- Pro forma annual revenue growth of 6% to 8% (excluding the $7.1 million GE Healthcare contract reset)
For full-year 2026, management maintained guidance:
- Annual revenue growth of 6% to 8% on a pro forma basis
- Adjusted EBITDA margin in the low to mid 20% range
Management emphasized that ERP-related costs will taper in the back half of the year, with system benefits expected to emerge in 2027. Wound care and compression device adoption are cited as key drivers for achieving the high end of revenue guidance.
- ERP stabilization and process optimization in coming quarters
- Oncology RCM migration on track for late 2026
Takeaways
InfuSystem’s Q1 illustrates a business in transition, with patient services and wound care scaling rapidly to offset legacy contract headwinds. Margin expansion and disciplined capital allocation are providing resilience as the company invests in technology and partnerships to drive future growth.
- Wound Care and Compression Devices: Segment is emerging as a growth engine, with new partnerships and reimbursement stability supporting double-digit expansion potential.
- ERP Integration: Short-term costs are peaking, but the platform is expected to deliver material productivity and margin gains starting in 2027.
- Device Solutions Reset: Success in pivoting to higher-margin, service-oriented work will be critical for segment relevance and overall earnings quality.
Conclusion
InfuSystem’s Q1 2026 results reflect a deliberate shift toward higher-value, patient-centric growth, with wound care and ERP investment at the center of its evolving business model. Margin expansion and operational discipline are cushioning the impact of legacy contract resets, while technology integration and new partnerships set up the company for improved returns and resilience in future periods.
Industry Read-Through
InfuSystem’s wound care surge and ERP-driven transformation offer a microcosm of broader healthcare services trends: legacy device and rental models are giving way to patient-centric, partnership-driven growth, and technology is becoming a core differentiator for margin and efficiency. Other device rental and service providers will face similar pressures to shift toward higher-margin, less capital-intensive offerings and to invest in data-driven platforms that enable pricing, utilization, and working capital optimization. The speed and effectiveness of ERP rollouts, as well as the ability to secure strong reimbursement partnerships in compression and wound care, will be key competitive battlegrounds across the sector.